Clinical Trial

To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients with Transthyretin Amyloid Polyneuropathy
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-15.
Status change: Not Yet Recruiting → Recruiting 2025-07-29
Trial Details
NCT Number NCT06940336
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Transthyretin Amyloid Polyneuropathy
Enrollment 15 participants
Start Date 2025-06-19
Primary Completion 2028-01 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2025-07-30